JP2012532094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532094A5 JP2012532094A5 JP2012516964A JP2012516964A JP2012532094A5 JP 2012532094 A5 JP2012532094 A5 JP 2012532094A5 JP 2012516964 A JP2012516964 A JP 2012516964A JP 2012516964 A JP2012516964 A JP 2012516964A JP 2012532094 A5 JP2012532094 A5 JP 2012532094A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- protofibril
- oligomer
- terminal truncated
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960005486 vaccine Drugs 0.000 claims 6
- 239000000178 monomer Substances 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| US61/221,105 | 2009-06-29 | ||
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083057A Division JP6884025B2 (ja) | 2009-06-29 | 2017-04-19 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532094A JP2012532094A (ja) | 2012-12-13 |
| JP2012532094A5 true JP2012532094A5 (enExample) | 2013-08-08 |
Family
ID=42832352
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516964A Withdrawn JP2012532094A (ja) | 2009-06-29 | 2010-06-29 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| JP2017083057A Active JP6884025B2 (ja) | 2009-06-29 | 2017-04-19 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| JP2019142344A Pending JP2019218362A (ja) | 2009-06-29 | 2019-08-01 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083057A Active JP6884025B2 (ja) | 2009-06-29 | 2017-04-19 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| JP2019142344A Pending JP2019218362A (ja) | 2009-06-29 | 2019-08-01 | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (enExample) |
| EP (2) | EP3892633A1 (enExample) |
| JP (3) | JP2012532094A (enExample) |
| AU (1) | AU2010267640B2 (enExample) |
| CA (1) | CA2765602C (enExample) |
| CY (1) | CY1124034T1 (enExample) |
| DK (1) | DK2448968T3 (enExample) |
| ES (1) | ES2864049T3 (enExample) |
| HR (1) | HRP20210611T1 (enExample) |
| HU (1) | HUE053949T2 (enExample) |
| LT (1) | LT2448968T (enExample) |
| PL (1) | PL2448968T3 (enExample) |
| PT (1) | PT2448968T (enExample) |
| SI (1) | SI2448968T1 (enExample) |
| SM (1) | SMT202100237T1 (enExample) |
| WO (1) | WO2011001366A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CN101421303B (zh) | 2006-03-23 | 2013-06-12 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| HRP20180230T8 (hr) | 2010-02-26 | 2021-04-30 | Bioarctic Neuroscience Ab | Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija |
| SG192805A1 (en) | 2011-03-16 | 2013-09-30 | Probiodrug Ag | Diagnostic antibody assay |
| MY184890A (en) | 2014-07-10 | 2021-04-29 | Bioarctic Neuroscience Ab | Improved a? protofibril binding antibodies |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| EP3484918A1 (en) | 2016-07-14 | 2019-05-22 | BioArctic Neuroscience AB | Brain delivery protein |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| JP7541505B2 (ja) | 2018-07-24 | 2024-08-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病の治療及び予防方法 |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20220251518A1 (en) * | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| FI4172199T3 (fi) | 2020-06-26 | 2025-08-12 | Bioarctic Ab | Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet |
| EP4367516A1 (en) | 2021-07-09 | 2024-05-15 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| EP4395821A1 (en) | 2021-08-30 | 2024-07-10 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| US20250377367A1 (en) | 2022-02-02 | 2025-12-11 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| KR20250134612A (ko) | 2022-12-22 | 2025-09-11 | 바이오악틱 에이비 | Abetape3에 결합하는 항체 |
| US20250388664A1 (en) | 2024-06-20 | 2025-12-25 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| WO2001010900A2 (en) * | 1999-08-04 | 2001-02-15 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
| JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1911765A3 (en) * | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
| EP2067789A1 (en) * | 2004-04-13 | 2009-06-10 | F. Hoffmann-La Roche Ag | Anti-P selectin antibodies |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EA016357B1 (ru) * | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Антитела, направленные против бета-амилоидного пептида, и способы их применения |
| CN101421303B (zh) * | 2006-03-23 | 2013-06-12 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| MY158903A (en) * | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
| ES2709048T3 (es) * | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
-
2010
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532094A5 (enExample) | ||
| ES2973425T3 (es) | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2) | |
| AU2018200886B2 (en) | Compositions and methods for treating and preventing Staphylococcus aureus infections | |
| JP2022031635A5 (enExample) | ||
| Proctor | Recent developments for Staphylococcus aureus vaccines: clinical and basic science challenges | |
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2015523962A5 (enExample) | ||
| JP2013524774A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| JP2016533335A5 (enExample) | ||
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2012504602A5 (enExample) | ||
| JP2018529635A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2013538796A5 (enExample) | ||
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| KR20200104314A (ko) | Lag-3 항체 약학 조성물 및 이의 용도 | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| IN2014CN04823A (enExample) | ||
| RU2013101769A (ru) | Высокоаффинные антитела человека к белку gb цитомегаловирусу (смv) человека | |
| EP2778173A1 (en) | Antibody directed against anthrax toxins and its uses |